[EN] NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS<br/>[FR] NOUVEAUX COMPOSÉS D'IMIDAZOLIDINE EN TANT QUE MODULATEURS DU RÉCEPTEUR D'ANDROGÈNE
申请人:GALAPAGOS NV
公开号:WO2010029119A1
公开(公告)日:2010-03-18
Novel compounds are disclosed that have a Formula represented by the following: wherein X, R1, R2a, R2b, R2c, R3a R3b, R4a, R4b, R4c, and ml are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non- limiting example, cachexia, osteoporosis, sarcopenia, a decline in libido and/or sexual dysfunction.
CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S
申请人:Ameriks Michael K.
公开号:US20080200454A1
公开(公告)日:2008-08-21
Carbon-linked tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.
Effect of Substitution on the Intramolecular 1,3-Dipolar Cycloaddition of Alkene Tethered Münchnones
作者:Guillaume Bélanger、Myriam April、Étienne Dauphin、Stéphanie Roy
DOI:10.1021/jo061556t
日期:2007.2.1
dipolarophile and the münchnone on the intramolecularcycloaddition outcome was examined. It was found that either nonactivated or electron-poor alkenes can react with the münchnone if these alkenes are tethered at position 4 on the münchnone (2, R2 = alkene tether), whereas only an electron-poor alkene at position 2 (2, R3 = alkene tether) could undergo successful cycloaddition. Also, münchnones substituted
[EN] PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS<br/>[FR] PYRROLIDINE-PYRAZOLES EN TANT QU'ACTIVATEURS DE LA PYRUVATE KINASE
申请人:GLOBAL BLOOD THERAPEUTICS INC
公开号:WO2021202796A1
公开(公告)日:2021-10-07
The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
Expedient Syntheses of Sulfonylhydantoins and Two Six-Membered Analogues
作者:Andrew D. Campbell、Alan M. Birch
DOI:10.1055/s-2005-863735
日期:——
A range of α-amino esters can be turned into sulfonylhydantoins 2 in a single, atom-economic step using sulfamide and DBU. This procedure obviates the need for a three- or four-step sequence utilised by traditional procedures. Two new six-membered analogues 3 and 4 have also been prepared utilising novel synthetic protocols.